The Mafia of Pharma Pricing

Role and Incentives of PBMs and Insurers

• PBMs are highly consolidated and often owned by large insurers/healthcare conglomerates.
• Because insurance profits are capped as a % of medical spend, shifting margin into PBMs circumvents caps: PBMs overcharge insurers, insurers raise premiums, the parent company keeps the spread.
• Insurers are not viewed as primary “victims”; they can pass costs to employers and patients and have weak incentives to push prices down.
• PBMs use secret rebates and formulary control to steer volume, keep generics off formularies, and justify high list prices while claiming big “discounts.”

Impact on Patients and Providers

• Insured patients usually pay copays, not list price, but ultimately bear costs through higher premiums and narrower coverage.
• Uninsured or temporarily “out-of-network” patients get hit with inflated list prices, e.g., insulin.
• Stories of doctors and urgent care pushing tests or devices seemingly aligned with manufacturer payments raise concerns about conflicts of interest.
• Some patients bypass the system via imports or buyers’ clubs, highlighting how broken the domestic market feels.

Data, IT, and Privacy Practices

• First-hand accounts describe PBMs as merger-heavy, technically messy organizations using “innovation labs” as client-facing theater.
• There is a substantial business in selling or “rebating” around de-identified or consent-waived medical data; posters question why this is legal but note HIPAA waivers and lobbying.
• Concerns about mandatory IDs/phone numbers, data leaks, and weak consequences for breaches.

Regulation, Capture, and System Design

• Multiple commenters frame the mess as regulatory design and capture: safe harbors for rebates, 340B distortions, Medicare’s limited price negotiation, import restrictions.
• Others counter that some regulation is necessary (safety/efficacy), and that the U.S. problem is bad or captured regulation, not regulation per se.
• Debate over whether vertical integration (insurer–PBM–pharmacy) should be explicitly prohibited.

Drug Costs, R&D, and Alternatives

• Biotech insiders emphasize real scientific difficulty and cost; others note heavy public funding, marketing outlays exceeding R&D in some cases, and patent games.
• Disagreement over whether high profit margins are justified by past R&D costs.
• Proposed remedies include price transparency, banning certain kickback exemptions, stronger antitrust, direct price regulation, or more public ownership/funding of drug development.